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ABSTRACT  
The present treatments for HIV transfection include chemical agents and gene therapies. Although many chemical drugs, peptide s and genes 
have been developed for HIV inhibition, a variety of non-ignorable drawbacks limited the efficiency of these materials. Dendrimers has ability to 
carrier of antiviral drugs due to some properties such as mono-dispersity, defined structure, amenability for functionalization using diverse 
ligands and its low-nanometer size. In this review, we discuss the application of dendrimers as both therapeutic agents and non-viral vectors of 
chemical agents and genes for HIV treatment. In one way, dendrimers with functional end groups combine with the gp120 of HIV and CD4 
molecule of host cell to suppress the attachment of HIV to the host cell. In another way, dendrimers are also able to transfer chemical drugs and 
genes into the host cells, which increase the anti-HIV activity of these materials. Dendrimers as therapeutic tools provide a potential treatment 
for HIV infection. 
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Dendrimers are macromolecules with a defined globular 
shape that were synthesized for the first time at the end of 
the 1970s. They are sophisticated and curious molecules 
and have attracted the interest of chemists owing to their 
potential applications in different areas, such as catalysis, 
materials science and biomedicine[1].One of the most 
attractive applications in the biomedical field is the use of 
functionalized dendrimers as antiviral agents. These 
dendrimers are able to form stable complexes with viral 
structures or receptors at the cell surface, resulting in 
disruption of the virus–cell interaction during the infection 
process. Dendrimers have emerged as important tools for 
drug discovery because of their ease of surface 
modification as well as their ability to interact with 
charged functional groups.  This review suggest that 
dendrimers may have applications in prion infections. 
They are also very efficient anti-virals, acting by both 
inhibiting cell entry and preventing replication of 
pathogens. They have shown immense potential to act 
against HIV. The life cycle of HIV comprises a number of 
steps: first, HIV attach to the host cell and fuses with the 
membrane; then, the viral RNA reverse transcripts to form 
DNA and integrates into the host cell’s DNA; next, mRNA is 
formed via transcription and protein expresses; finally, the 
new virus is assembled automatically. Each of the steps 
could be considered as the target for intervention [2]. A lot 
of polymers, chemical agents and gene therapies are 
widely used to block these two steps for HIV replication, 
yet most of the treatments are lacking in effectiveness [3]. 
The dendrimers have been designed with specific 
functional end groups to preferentially interact with the 
envelope protein of HIV and receptors on the host cells in 
order to suppress the combination between HIV and host 
cells and later stages of HIV replication [4].  The 
dendrimers with large amounts of peripheral groups and 
interior cavities are potential vectors for chemical drugs, 
peptides and genes for HIV inhibition. These materials are 
capable to either interacting with the peripheral groups or 
be encapsulated into the cavities of dendrimers with 
hydrogen bonds, electrostatic and hydrophobic 
interactions [5, 6]. Other anionic polymers acting on target 
HIV, and to the nucleotide or non-nucleoside reverse 
transcriptase inhibitors or the integrate inhibitors acting 
on intracellular targets [7, 8, 9, 10]. 
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Antiviral activity of dendrimers  
 Dendrimers used as antiviral agents has been one of the 
most successful avenues in dendrimer-based drug 
discovery. Dendrimers either prevent binding of viruses to 
the target cell surface or prevent replication of the viral 
genome. The ability to prepare a diverse array of 
dendrimers, patterns of biological activity can be 
investigated where subtle changes in the dendrimer design 
parameters type of initiator, branching unit type, 
dendrimer generation, linker, and surfaces may have a 
bearing on the biological properties of the individual 
dendrimers. 
Prevention of virus binding to the target cell surface 
Multiple carbohydrate binding proteins present on viruses 
play a critical role in invasion of the host cell. 
Carbohydrates present on the target cell surface can be 
linked to various dendrimers, which can act as receptors 
for viruses. Thus, glycodendrimers with carbohydrates at 
the periphery were tested for their ability to prevent 
binding of the influenza virus to host cell surface 
carbohydrates.[11,12] Carbosilane dendrimers 
functionalized with sialyllactose (a trisaccharide) were 
also found to be effective inhibitors of influenza hem 
agglutinin induced agglutination of erythrocytes.[13] The 
non-cytotoxic polysulfated galactose derivatised 
poly(propyleneimine) dendrimers inhibit the infection of 
laboratory-isolated HIV-1 as efficiently as dextran 
sulfate.[14] Sulfonated polylysine dendrimer with a 
benhydrylamine core has been shown to inhibit viral 
absorption[15]. The anti-HIV activity of dendrimers and 
glycodendrimers is being extensively studied. A recent 
study indicated that PPI and manosylated PPI dendrimer 
alone possess some anti-HIV activity. These nanocarrier 
systems are being explored further for controlled and 
targeted delivery of anti-HIV drugs[16]. 
Dendrimer based drug targeted approach 
Dendrimers highly branched nanocarriers. The surfaces of 
dendrimers can be easily functionalized due to the 
availability of multiple functional groups. Dendrimers have 
been investigated for the delivery of drugs across the 
BBB. Polyether-co-polyester dendrimers containing the 
cytotoxic drug methotrexate were conjugated to D-
glucosamine to enhance the BBB permeability in order to 
deliver high amounts of drug to the CNS[17]. In another 
study, lamivudine-loaded mannosylated PAMAM 
dendrimers were evaluated for their in vitro antiretroviral 
activity in HIV-infected MT2 cells. It was observed that 
following encapsulation within dendrimers, lamivudine 
exhibited greater antiretroviral activity as a result of 21-
fold higher drug uptake when compared to drug in 
solution [17].In this study designed PAMAM having PEG 
grafts as a novel drug carrier. PEG were combined to 
essentially every chain of dendrimers with the generation 
G4 and G5. Moreover we prepared the PEGylated PAMAM 
dendrimers encapsulating the anti-HIV drug lamivudine. 
While encapsulating ability of PEGylated PAMAM 
dendrimers are increased when compared with non-
PEGylated PAMAM dendrimers. Performed drug release 
studies of PEGylated PAMAM dendrimers showed prolong 
drug release for longer time when compared with non-
PEGylated PAMAM dendrimers[18]. In this study 
successfully synthesized and conjugated PEGylated 
PAMAM dendrimers with anti HIV drug stavudine. 
Hemolytic toxicity studies were carried out for PEGylated 
PAMAM dendrimers which showed that haemolysis of cell 
was very negligible in PEGylated PAMAM dendrimers[19]. 
5.0 G EDA PAMAM dendrimers were synthesized and 
PEGylated using PEG 600 using epichlorhydrin as cross-
linking agent. PEGylated 5.0 G PAMAM dendrimers loaded 
with Efavirenz (EFV) the results it is proved that 
PEGylated 5.0 G PAMAM-EFV dendrimers have shown 
prolonged drugrelease property [20]. 
Glycodendrimers 
These are dendrimers presenting at their surface multiple 
copies of carbohydrates, have been recently developed and 
are excellent tools with which to address carbohydrate–
protein interactions in biological processes at the 
molecular level and also to study the multivalent effect 
[21]. Carbohydrates confer to these systems high 
selectivity to interact with specific lectin receptors; 
however, until recently, few glycodendrimers have found 
biomedical applications. For instance, one of these 
applications enables these molecules to interact with 
Fimbrae protein to avoid infection by Escherichia coli[22]. 
Another interesting example is a fourth-generation 
PAMAM dendrimer conjugated with sialic acid.[23,24] 
These sialic acids present at the dendrimer surface are 
able to interact with haemagglutinin, the major surface 
glycoprotein of influenza A virus, and prevent viral 
adhesion to target cells exhibiting sialic acid at their 
surfaces. This activity has been tested in vitro and in vivo 
using a murine influenza pneumonitis model [25].To the 
best of our knowledge, this is the only example described 
of glycodendrimers as antiviral drugs. In this one, the main 
antiviral strategy so far has been based on the binding of 
the dendrimer to the viral surface. However, many viruses, 
such as influenza A virus or HIV, present a high degree of 
mutation leading to major changes in the envelope protein 
glycosylation patterns when comparing the different 
strains. This is one of the reasons why the development of 
a viral vaccine is so elusive in these particular cases. The 
glycopeptide dendrimers have been used in several ways 
such as antitumor and antiviral prophylactic or therapeutic 
vaccines[21]. 
Prevention of HIV Attachment to the Surface of Host 
Cells 
CD4 Receptors 
HIV infection starts with attachment of envelope protein 
gp120 to CD4 molecules on the host cell surface, followed 
by engagement of chemokine receptors (CXCR4 and CCR5) 
to form a CD4-gp120-chemokine receptor complex. 
Subsequently, envelope protein gp41 of the virus mediates 
the membrane fusion [26]. The dendrimers with 
functionalized end groups were present that were 
developed to combine with gp120 or CD4 molecules to 
impede the subsequent steps of HIV infection. The 
discovery of the mechanism of HIV inhibition, two 
polyanionic dendrimers BRI2932 (SPL2923) and BRI6195 
(SPL6195) was found to inhibit the replication of HIV 
(strain IIIB) at an EC50 of 0.1 and 0.3 μg/mL respectively, 
with extremely low cytotoxicity to the host cells. A gp120 
binding assay and virus adsorption assay indicated that 
both compounds have an effect on the docking of HIV to 
the host cells. The SPL2923 at higher concentration could 
also block the later stages of HIV infection. 
Correspondingly, results from cellular uptake experiments 
testified that SPL2923 was capable of invading the host 
cell, whereas SPL6195 was not [27]. 
DC-SIGN Receptors 
DC-SIGN receptor is a tetrameric C-type lectin mainly 
presented on the surface of immature dendritic cells (DCs) 
for modulating the immune response against pathogen 
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[28,29]. In previous studies, DC-SIGN was testified as the 
receptors of a number of pathogens, including Ebola, 
simian immuno-deficiency virus (SIV), HIV and 
cytomegalovirus. The mechanism of DC-SIGN to act as a 
receptor had been exploited with high affinity for mannose 
glycans moieties on the pathogens [30,31,32]. For instance, 
HIV possesses a high density of the Man-α1,2-Man motif on 
the gp120 [33].  Thus, a nucleic acid-encoded carbohydrate 
library that focused on mannose and its derivatives 
suggested that an assembly of mannose with an aryl group 
at the 6-position of the terminal unit is beneficial for DC-
SIGN binding. The binding affinity of the assemblies to DC-
SIGN was measured and the assembly with highest affinity 
was covalently bound to PAMAM. The studies on the 
assembly modified PAMAM showed intensive inhibition on 
the interaction between gp120 and DCs at 10 μM  (60 μM 
in mannose), whereas a natural polymer of mannose-
mannan only partially inhibited the interaction at 500 μM 
in mannose [34]. 
Glycosphingolipids (GSLs) 
In non-CD4-expressing cells the potential binding 
receptors of HIV have been supposed to be  GSLs [35,36]. It 
has been verified by several studies that the gp120 of HIV 
virus would bind with the GSLs for cell entrance [37]. the 
dendrimer-based antagonists for HIV could be changed  
with carbohydrates moieties to mimic the local spatial 
structure of GSLs. Galactose [38], cellobitose [39,40], 
globotriose and 3’-sialyllactose [41] have been employed 
as functional dendrimer end groups to suppress 
attachment of HIV to host cells. In conformity with the 
previous compounds, both of the galactose and cellobitose 
were sulfated to achieve effective inhibition activity. 
The interactions between particular  sulfate and V3 loop of 
gp120 was confirm  by  Richard and colleagues [42], 
implementation of the inhibition of gp120 adherence to 
immobilized sulfatide by galactosyl ceramide (GalCer), 
sulfatide galactosyl ceramide (SGalCer), ceramide, dextran 
sulfate (DxS), and chondroitin sulfate (ChS). The previous 
studies showed that GalCer and its 3-sulfated derivative-
SGalCer had high affinity to gp120 which mediated the 
HIV-1 infection, and a series of analogs of GalCer-modified 
dendrimers showed impressive anti-HIV activity [43, 44]. 
The galactose moieties were modified on a poly- 
propylenimine tetrahexacontaamine dendrimer (PS Gal 
64mer). The dendrimer with specific position C-3 sulfate 
modified galactose, akin to SGalCer, was certified by the 
HIV inhibition [45].  The positions were compared with the 
position-specifically sulfated galactose modified 
dendrimer, randomly sulfated cellobitose was connected 
to a generation 3 polylysine dendrimer (PLDG3). The anti-
HIV activity assay demonstrated that PLDG3 had less 
antiviral activity than dextran sulfate, curdlan sulfate and 
azidothymidine (AZT), but similar activity to 
dideoxycytidine (ddC). The low molecular weight of 
oligosaccharides (such as cellobitose) have little or no anti-
HIV activity [46], the high biological activity of PLDG3 was 
ascribed to the cluster effects of sulfated cellobitose on 
PLDG3 [47]. In addition, the sulfated cellobitose functional 
group was also attached to an amphiphilic lysine 
dendrimer (SCSLD3), which was covalently bound to a 
stearylamide. The long stearyl chains were  interact with 
the HIV lipid bilayer and destroy the HIV  lipid bilayer,  
similarly to the function of surface active agents with both 
hydrophilic (sulfated cellobitose) and hydrophobic ends 
(stearyl chain) [48]. The preliminary anti-HIV activity of 
SCSLD3 was determined to have as high activity as PLDG3 
[49]. 
Prevention of Replication of HIV in Host Cells 
Polycationic Dendrimers 
Unmodified polycationic dendrimers-PAMAM have been 
developed to inhibit binding of Tat protein to trans-acting 
responsive element (TAR) RNA of HIV [50,51]. The cationic 
molecules were also  including polyamine acridine based 
compounds [52] and polyallylamine hydrochloride (PAH) 
[53], which interacted with TAR RNA through electrostatic 
forces. A kind of polycationic based dendrimer with 
excellent activity against replication of HIV-1 was 
developed. The dendrimers were inhibited HIV-1 
replication in MT-4 cells while they showed no inhibitory 
activity in human PBMC. The distinct anti-HIV activities 
were in line with the expression of heparan sulfate in the 
host cells. Thus, the inhibition of HIV replication was 
ascribed to the block of interactions between virus and 
heparan sulfate on the cell surface. This assumption was 
testified by the detection of charge distance of dendrimer 
moieties and heparan sulfate disaccharide unit. Besides, 
the dendrimers with spheroidal structure exhibited higher 
inhibition activity than those with comb-branched 
structures [54]. 
Polyanionic Dendrimers 
Polyanionic dendrimers were also inhibits the HIV. The 
first developed compound SPL2923 has been found to 
have an effect on the reverse transcription process at a 
concentration of 100 μg mL-1 (5-fold of the concentration 
used for inhibiting the attachment to host cells). However, 
SPL 6195 could not penetrate into the host cells and 
interfere with the later stages of HIV infection, even if the 
concentration of the compound was increased 5-fold. It 
was reasonable to conclude that the differences on the 
core structure and peripheral groups of dendrimers 
definitely affected their capability to restrain the 
replication of HIV [55]. The SPL7013 and SPL7115 were 
inhibits the HIV-1 virus , and the results suggested that 
SPL7013 was capable of inhibiting the activity of reverse 
transcriptase (RT) of HIV-1. 
Dendrimers Acting as Potential Vectors for Drugs and 
Genes 
The anti-HIV chemical drugs have shown broad treatment 
failure and adverse effects which are related to their low 
cytotoxicity and high plasma concentration of drugs. 
Dendrimers as an ideal carrier could effectively bring the 
anti-HIV drugs into HIV-infected cells and take the place of 
virus to transfer genes into nucleus of HIV-infected cells in 
order to effectively interfere with the replication of HIV. 
Dendrimers as Carriers for Chemical Drugs 
The chemical anti-HIV drugs widely used for inhibition of 
reverse transcription are divided into three categories: 
nucleoside analogue reverse transcriptase inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI) and protease inhibitors (PI). Efavirenz (EFV), 
lamivudine (3TC), zidovudine (AZT) and didanosine (ddI) 
are the most studied anti-HIV drugs due to their most 
favorable resistance profiles. Except for EFV, the others are 
all NRTIs. As monocytes/macrophages (Mo/Mac) were 
supposed to be the reservoir of HIV and played an 
important role on dissemination of virus throughout the 
body, antiretroviral drugs were expected to specifically 
intrude the Mo/Mac [56]. Lectin receptors were reported 
to be presented on the surface of the Mo/Mac [57,58]. 
Thus, connected with saccharides was supposed to be the 
most efficient way for drugs to get into Mo/Mac via 
combination of saccharides and lectin receptors [59,60]. 
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Dendrimers as Carriers for Genes 
Gene therapies for HIV inhibition can be divided into two 
categories: (1) oligodeoxynucleotides (ODNs) involving the 
HIV polypurine tract element mRNA (PPT), HIV anti-
transactivation responsive gene (TAR), HIV gene 
expression modulator 91 (GEM 91), HIV replication mRNA 
(REV) and a random mix of two of the ODNs to form a 
cocktail; (2) siRNA involving three sequence: siP24, 
siGAG1, siNEF and cocktails. The genes were transferred 
into cells via viral vectors. However, the use of viral 
vectors suffered from several defects. The viral vectors 
would induce severe immune reactions. The genes would 
bind non-specifically to serum proteins which decreased 
the bioactivity and induced toxic effect [61]. Thus, a new 
non-viral vector was required to play the role of gene 
carriers. 
Oligodeoxynucleotides (ODNs) 
The first to employ 2G-NN8 and 2G-NN16 as carriers for 
ODNs to form dendriplexes. The studies showed that the 
dendriplexes were able to protect ODNs from binding to 
both bovine serum albumin (BSA) and human serum 
albumin (HSA). The dendriplex formed by 2G-NN16 and 
TAR was shown by confocal microscopy to be internalized 
into the PMBC, and the ODNs alone showed non-sequence 
specific inhibition effects on PBMC and lymphocyte T-cells 
(MT-2), however, the dendriplexes exhibited sequence 
specificity in HIV inhibition to some extent [63]. 
siRNA 
As a carrier for siRNAs, 2G-NN16 provided a strong 
protection for siRNA challenged with heparin and 
ribonuclease (RNase). The dendriplexes was implemented 
on both Sup T1 cells and HIV-infected PBMC. Interestingly, 
naked siRNA showed successful uptake by Sup T1 cells, but 
was unable to enter the HIV-infected PMBC during the first 
3 hours. The dendriplexes shows the highest transfection 
efficiency at a 2G-NN16/siRNA ratio of 1 or 2.  The higher 
+/− charge ratios would inhibit the viability of cells. The 
naked siRNA showed sequence-specific and concentration-
dependent activity against the housekeeping gene 
(GAPDH) in uninfected SupT1 cells and HIV replication in 
infected PMBC via electroporation. The dendriplexes was 
tested directly on cells. The results indicated that the 
dendriplexes possessed higher inhibition activity on 
GADPH in SupT1 cells and HIV-infected PBMC than naked 
siRNAs, especially with the cocktails of siRNA [63]. 
Carbosilane dendrimer, polycationic dendrimer PAMAM 
and phosphorus-containing dendrimer-G4 (NH+Et2Cl-)96 
had been developed as carrier for gene therapies as well. 
The PAMAM and siRNAs, especially the cocktails, formed 
dendriplexes that not only exhibited conspicuous 
inhibition of HIV replication in vitro, but also effectively 
suppressed HIV infection in viremic RAG-hu mice[63]. 
CONCLUSION 
The current status of dendrimer-based therapies for the 
treatment of HIV infection, and highlight the potential role 
of dendrimers as both therapeutic agents and non-viral 
vectors. As dendrimers have a lot of peripheric active 
groups, modified dendrimers have the ability to 
specifically combine with gp120 or CD4 molecule in order 
to block the attachment of HIV to the host cell. The 
application of dendrimers as carriers of chemical agents 
and genes is impressive. The dendrimers improve the 
efficiency of cellular uptake and anti-HIV activity on host 
cells, while the anti-HIV activity of the dendrimer-based 
formulations is not perfectly in accordance with the 
cellular uptake results. Hence, it’s concluding that the 
release profile of drugs and the degradation ability of 
dendriplexes play an important role for anti-HIV activity. 
In conclusion, the explanation of dendrimer based drug 
delivery form will help in ART therapy by minimizing the 
drug resistance of anti-viral molecules. The   dendrimers 
with specific functional groups offer significant benefits to 
prevent HIV infection. 
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